What’s driving the uptake of biosimilars in Europe and what still needs to be done?
The European market for biosimilars has seen a year of progress and change, with more therapies available and changing attitudes from many payers. Driven by the pressing need to control drug costs, payers have notably moved their position in key areas such as interchangeabilty and indication extrapolation. But where are the sticking points? What are the critical factors for success? What more could the biosimilar industry do to help its cause?
This report identifies the issues that payers identify as critical to the continued growth and adoption of biosimilars. Biosimilars: European Payer Perspectives is informed with candid insights of 15 European payers from the five leading European markets and packed with actionable information. It is essential reading for all commercial and research planners in branded and biosimilar manufacturers.
“The key reimbursement challenge at the moment comes down to the four-letter word of cost: every healthcare organisation is really struggling to contain cost.”
Answering key questions:
With this report you will be able to:
Key Topics explored
For this report FirstWord has interviewed 15 payers, 3 from each EU5 country. Payers interviewed have direct experience of assessing biosimilars for inclusion on formulary, either as part of a committee or as the lead decision-maker./Paragraph>
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Table of Contents
for Biosimilars: European Payer Perspectives (2016) [Published by FirstWord Pharma]
2 Executive summary
3 Research objectives and methodology
4 Biosimilars in Europe: Where we currently stand
4.1 Biosimilar approvals in Europe to date
4.2 Uptake and usage of biosimilars in Europe
5 Awareness and perceptions of biosimilars
5.1 Key insights
5.2 Awareness of biosimilars at the payer level is generally high, and physician awareness is increasing
5.3 Physician acceptance on the rise, but varies by disease area, with biosimilars most common in acute settings
6 Key influencers on biosimilar adoption in 2015
6.1 Key insights
6.2 Biosimilar adoption buoyed by local policy changes, prescribing initiatives over the past year
6.3 Payers identify clinical and real-world data as leading reason for improved biosimilar adoption
6.4 Physicians and HTA bodies are pushing biosimilar acceptance, but patient advocacy groups are not providing much support
6.5 How has the biosimilar regulatory approval timeline changed over the past 12 months? 15
6.6 How has the importance of the potential cost savings associated with biosimilars changed in the past 12 months?
7 The current regulatory environment
7.1 Key insights
7.2 Regulatory data requirements mostly satisfy payers, but some would prefer additional clinical comparability data and information on interchangeability
7.3 Small, clinically non-significant differences between biosimilars and their reference products are permissible
7.4 Real-world, interchangeability data could provide assurance that biosimilars are comparable to reference products
8 Recent policy events shaping the biosimilars market
8.1 Key insights
8.2 EMA’s guideline on biosimilars goes into effect, provides guidance on clinical trial comparators
8.3 European Biosimilars Group asks EFPIA to clarify its policy on off-patent biological drugs
8.4 NHS England position statement seeks to define concept of biosimilar medicine
8.5 Ireland’s HPRA published guide on biosimilars, outlining recommendations for indication extrapolation and interchangeability
8.6 Finland’s Fimea proposes hospital-level interchangeability, but rules against pharmacy-level substitution
9 Biosimilar naming rules
9.1 Key insights
9.2 Payers argue benefits of existing name proposals, suggest alternative traceability strategies
9.3 Payers express concern that WHO’s Biological Qualifier proposal could add layer of confusion
9.4 Biosimilar naming should promote traceability without drawing attention to differences, payers suggest
10 Interchangeability, substitution and indication extrapolation
10.1 Key insights
10.2 Payers agree that physicians should have the final say on substitutions, but say there is room for regulatory oversight
10.3 Payers undecided when switching should be permissible
10.4 Additional data on switching outcomes could boost biosimilars, but not yet clear who should collect such data
10.5 Barriers to greater biosimilar interchangeability are varied
10.6 Other factors limiting interchangeability:
11.1 Key insights
11.2 How biosimilars are reviewed for inclusion on formularies
11.3 Payers suggest formulary decision-making process will be streamlined by experience
11.4 Requirements for adding biosimilars to formularies vary by country, but do not differ
11.5 significantly from traditional medicines or generics
11.6 Payers increasingly comfortable with adding biosimilars to formularies, but could limits on numbers be imposed?
12.1 Key insights
12.2 How decisions on biosimilar prices are made
12.3 Payers suggest 20 percent discount for biosimilars is a good place to start
12.4 Norway, Denmark’s near 70 percent discount for infliximab turns heads, but not likely to be replicated
12.5 Not yet clear which European countries are leading the way on biosimilar pricing
12.6 Payers remain unclear on appropriate level of pricing discounts for biosimilars, but price matching not likely
12.7 UK payers question longevity of Pharmaceutical Price Regulation Scheme to hold down costs
12.8 Prescribing targets and quotas may boost biosimilar prescribing, but results mixed to date
13 Future challenges and opportunities for biosimilars
13.1 Key insights
13.2 Potential future trends, challenges and opportunities for biosimilars in Europe
13.3 Europe likely to remain gold standard as it relates to biosimilar regulation, experts suggest
14.2 Experts interviewed for this report
|Title||Date Published||Price from||More Details|
| amp biosimilars AG (1YA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile|
Summaryamp biosimilars AG (amp biosimilars) is a biopharmaceutical company that develops biosimilars...
|24 Aug 2016 by Global Data||USD $220 (normally
| Biosimilars in Oncology: Update Bulletin [Feb 2016]|
Introduction new KOL insights on the latest events that have the potential to shape the oncology bio...
|01 Feb 2016 by FirstWord Pharma||USD $876 (normally
| Biosimilars in Oncology: KOL Insight|
IntroductionWill physicians ever adopt Biosimilars in Oncology?Sceptical, survival focussed oncologi...
|01 Jan 2016 by FirstWord Pharma||USD $6,952 (normally
| Biosimilars: Regulatory Outlook|
IntroductionBiosimilars offer a chance to improve access to, and reduce spending on, life-saving bio...
|01 Nov 2015 by FirstWord Pharma||USD $1,932 (normally
| The Future of Biosimilars 2015|
IntroductionThe Future of Biosimilars 2015 offers expert insight and opinion on the key issues facin...
|01 Jun 2015 by FirstWord Pharma||USD $1,932 (normally
| Biosimilars: US Payer Perspectives|
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
|01 Apr 2015 by FirstWord Pharma||USD $1,932 (normally
| Biosimilars: European Payer Perspectives|
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
|06 Jan 2015 by FirstWord Pharma||USD $1,932 (normally
| The Future of Biosimilars: mapping critical uncertainties and the impact of future events|
IntroductionThe Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Event...
|05 May 2014 by FirstWord Pharma||USD $1,716 (normally
| Commercialisation of Biosimilars: strategies for market penetration|
IntroductionTimes, they are a-changin’—at least for the American biological product market. With fiv...
|01 Nov 2013 by FirstWord Pharma||USD $612 (normally
| Biosimilars in Emerging Markets|
IntroductionWhat are the implications for regulators, biosimilar companies and branded manufacturers...
|01 Mar 2013 by FirstWord Pharma||USD $585 (normally
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.